InvestorLens

GANX — GAIN THERAPEUTICS INC

Public company

Sign in to save2 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying GANX?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
65
Institutional Conviction
Net distribution · 0 buying vs 0 selling last quarter
32
Macro Tailwind
Macro conditions are mixed for this sector
57
Why? — Evidence & Confidence ▾

No tracked investor changed their GANX position last quarter. Macro conditions are mixed for this sector (Macro Tailwind 57/100 in a Contraction regime).

Supporting evidence
  • +2 tracked investors reported holding GANX at their latest filing
  • +Macro Health is 57/100 in a Contraction regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/6/2026.

About GAIN THERAPEUTICS INC (GANX)

GAIN THERAPEUTICS INC (GANX) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by David Einhorn (DME Capital Management, LP), valued at $2M. Across recent filings, tracked investors recorded 2 new positions, 0 increased, 1 reduced, and 1 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in GANX

50
/100
Mixed Activity
Added / Increased2
Reduced1
Exited1
BearishBullish
Crowded Trade Score™

How many top investors track GANX

13
/100
Undiscovered
2investors

Only 2 tracked investors report this position.

UndiscoveredCrowded
151015+

GANX Ownership Composition

How GAIN THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Value & Distressed
74% of tracked value
Institutions
2
tracked investors
Total Reported
$1.5M
combined 13F value
Types2
  • Value & Distressed74.4%
  • Multi-Strategy / Quant25.6%
Value & Distressed(1)
74.4%
Multi-Strategy / Quant(1)
25.6%

Tracked investors currently reporting GANX

2 tracked investors have since exited this position — listed separately below.

  • David EinhornJun 30, 2026
    DME Capital Management, LP
    Shares
    566.1K
    Value
    $1.1M
    % Portfolio
    0.03%
  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    195.2K
    Value
    $396.3K
    % Portfolio
    0.00%

Previously held GANX

These investors reported GANX in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Izzy EnglanderMillennium Management14K$45.1KDec 31, 2025
Steve CohenPoint72 Asset Management32.5K$104.6KDec 31, 2025

Recent activity

Frequently asked questions

How many institutional investors hold GANX?
2 tracked institutional investors disclosed a position in GANX (GAIN THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of GANX?
David Einhorn, DME Capital Management, LP, holds the largest disclosed position in GANX, valued at $2M.
Did institutional ownership of GANX increase or decrease?
Across recent 13F filings, tracked investors recorded 2 new positions, 0 increased, 1 reduced, and 1 fully exited GANX.
Where does this GANX ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
GANX (GAIN THERAPEUTICS INC) — Institutional Holders & 13F — InvestorLens